DiaMedica Therapeutics Announces Late Breaking Data from REDUX Phase 2 Trial to be Presented at ASN Kidney Week 2021

Rhea-AI Summary

DiaMedica Therapeutics Inc. (NASDAQ: DMAC) announced that late-breaking data from its Phase 2 REDUX trial of DM199 for chronic kidney disease will be presented at the American Society of Nephrology's Kidney Week meeting. The presentation will include an update to interim data announced in June 2021. The session is set for November 4, 2021, highlighting ongoing research into DM199's effectiveness, a recombinant form of KLK1, which may address critical health issues including stroke and kidney disease.

Positive

• Presentation of late-breaking data at ASN Kidney Week demonstrates active research and development.
• Potential to improve treatment options for chronic kidney disease and acute ischemic stroke.

Negative

• None.

MINNEAPOLIS--(BUSINESS WIRE)-- DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, today announced that late-breaking data from the Company’s Phase 2 REDUX trial of DM199 in chronic kidney disease (CKD) will be presented at the American Society of Nephrology’s (ASN) annual Kidney Week meeting. The abstract will include an update to the Phase 2 REDUX interim data the Company announced in June 2021.

The ePoster session details are:

	Session Title:		Late-Breaking Clinical Trials Posters
	Session Release Date:		Thursday, November 4, 10:00 a.m. PDT (Pacific)
	ePoster number:		PO2526

The ASN Kidney Week 2021 will held virtually November 4-7, 2021. Additional information can be found here.

About DM199

DM199 is a recombinant (synthetic) form of human tissue kallikrein-1 (KLK1). KLK1 is a serine protease (protein) that plays an important role in the regulation of diverse physiological processes including blood flow, mitigating inflammation, fibrosis and oxidative stress and promoting neurogenesis via a molecular mechanism that, among other things, increases production of nitric oxide and prostaglandin. KLK1 deficiency may play a role in multiple vascular and fibrotic diseases such as stroke, chronic kidney disease, retinopathy, vascular dementia and resistant hypertension where current treatment options are limited or ineffective. DiaMedica is the first company to have clinically studied a pharmaceutically active recombinant form of the KLK1 protein. The KLK1 protein, in forms produced from porcine pancreas and human urine, has been used to treat patients in Japan, China and Korea for decades. DM199 is currently being studied in patients with acute ischemic stroke and chronic kidney disease.

About DiaMedica Therapeutics Inc.

DiaMedica Therapeutics Inc. is a clinical stage biopharmaceutical company committed to improving the lives of people suffering from serious diseases. DiaMedica’s lead candidate DM199 is the first pharmaceutically active recombinant form of the KLK1 protein, an established therapeutic modality for the treatment of acute ischemic stroke and chronic kidney disease. For more information visit our website at www.diamedica.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20211018005032/en/

Scott Kellen

Chief Financial Officer

Phone: (763) 496-5118

skellen@diamedica.com

For Investor Inquiries:

Tim McCarthy

Managing Director, LifeSci Advisors, LLC

tim@lifesciadvisors.com

Source: DiaMedica Therapeutics Inc.

FAQ

What is the REDUX trial for DM199?

The REDUX trial is a Phase 2 clinical study evaluating the effectiveness of DM199 in patients with chronic kidney disease.

When will the REDUX trial data be presented?

The data will be presented on November 4, 2021, at the ASN Kidney Week meeting.

What is DM199?

DM199 is a recombinant form of human tissue kallikrein-1, a protein that may help treat chronic kidney disease and acute ischemic stroke.

How does the REDUX trial update impact DMAC stock?

The presentation of clinical trial data can influence DMAC stock by reflecting ongoing advancements and potential market opportunities in treatment.